Loading
A phase 2 trial of KC1036, Toripalimab and Cisplatin in oesophageal cancer, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer is a phase 2 interventional study registered as NCT07481058 by Beijing Konruns Pharmaceutical Co., Ltd., with 60 participants planned, started 2025-12-12 and due to reach its primary completion in 2027-12. Interventions recorded: KC1036, Toripalimab, Paclitaxel and Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Konruns Pharmaceutical, KC1036 and the tag pipeline.
Shares Beijing Konruns Pharmaceutical, KC1036, Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/